Patients with pneumonia who test negative to RT-PCR

Pneumonia, Viral

Pneumonia, Bacterial

Coronavirus Infection

Obstructive Lung Disease

Antibody tests designed to provide results to individuals or healthcare providers can show whether someone was previously infected with SARS-CoV-2 being the RT-PCR negative for the population of patients

Serology for Covid-19

Fondazione Policlinico Universitario A. Gemelli IRCCS

Determinants of COVID-19 Pneumonia (MC-19)

Major Determinants of COVID-19 Associated Pneumonia

assess if inpatients who presented with pneumonia but had a negative test for Covid-19 are positive at the serology for SARS-CoV-2.

to find if the combination of CT scan and serology could help us in the identification of those patients who were initially negative at laboratory testing alone.

the efficacy of different pharmaceutical treatments against Covid-19

Geltrude Mingrone

Associate Professor of Internal Medicine

Catholic University of the Sacred Heart

Patients with pneumonia from Covid 19 with at least one of the following comorbidities:
Hypertension
Obesity and/or type 2 diabetes
Cardiovascular disease
Chronic obstructive lung disease

Without any of the following comorbidities

Hypertension

Diabetes Mellitus

Obesity

Cardiovascular Diseases

Prognostic Factors Keeping Track for COVID-19 Pneumonia

Time of Recovery and Prognostic Factors of COVID-19 Pneumonia

mean rate of recovery in patients with diagnosis of Covid-19 pneumonia, who present with complications at the time of hospital admission (such as diabetes, obesity, cardiovascular disease, hypertension or respiratory failure), with the mean recovery rate in patients without any of the above-mentioned complications.

comparison of the survival curves (times to improvement) in the two groups (patients with and without complications) and among patients presenting with different types of complications

the efficacy of different pharmaceutical treatment against Covid-19

liver, kidney or multiorgan failure, cardiac failure

Psoriasis

lower dose of Acitretin to 17.5 mg/day from 25 mg/day in those experiencing retinoid-related side effects

Acitretin 17.5 mg/day

Mount Sinai Clinical Trials

Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?

An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability

Improvement and maintenance of Psoriasis Area Severity Index (PASI), Body Surface Area (BSA), Physician's Global Assessment (PGA), and Psoriasis Disability Index and Dermatology Life Quality Index (DLQI)

Subjective efficacy/tolerability questionnaires for every subject at the end of the study

conjunctivitis/triglyceride

Determinants of COVID-19 Pneumonia (MC-19)

Prognostic Factors Keeping Track for COVID-19 Pneumonia

Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?

Najkompletnija baza ljekovitog bilja potpomognuta naukom